<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01370031</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-1008-PR-0049</org_study_id>
    <secondary_id>2010-022615-19</secondary_id>
    <nct_id>NCT01370031</nct_id>
  </id_info>
  <brief_title>Pilot Pharmacokinetic Clenil Study With AeroChamber Plus™ or Volumatic™ Spacer Devices</brief_title>
  <official_title>Pilot, Open-Label, Randomized, Repeated Dose, 4-Way Cross-Over, Clinical Pharmacology Study of Beclomethasone Dipropionate (Clenil® Modulite®) 250 µg HFA pMDI Using the Aerochamber Plus™ Spacer Device Versus the Volumatic™ Spacer Device Without or With Charcoal Block in Asthmatic Adults Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate, at steady-state, the systemic exposure and the lung
      deposition of B17MP (active metabolite of BDP) as AUC0-12h,ss and Cmax,ss, after inhalation
      of BDP (Clenil® Modulite®) with the AeroChamber Plus™ spacer device or with the Volumatic™
      spacer device without or with charcoal block.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systemic exposure to B17MP (active metabolite of BDP) at steady state after repeated dose of Clenil® Modulite®</measure>
    <time_frame>0-12 hours</time_frame>
    <description>Plasma AUC0-12h,ss for B17MP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic exposure to B17MP (active metabolite of BDP) at steady state after repeated dose of Clenil® Modulite®</measure>
    <time_frame>0-12 hours</time_frame>
    <description>Plasma Cmax,ss for B17MP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluation of the pharmacokinetic profile of BDP</measure>
    <time_frame>0-12 hours</time_frame>
    <description>AUC and Cmax for BDP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs assessment</measure>
    <time_frame>from screening (week -1) to week 8</time_frame>
    <description>Heart rate and Blood pressure assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>haematology and blood chemistry assessment</measure>
    <time_frame>at screening (week - 1) and week 8</time_frame>
    <description>haematology and blood chemistry assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Adverse events</measure>
    <time_frame>during the 11 weeks of study</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 predose assessment</measure>
    <time_frame>from screening (week-1) to week 8</time_frame>
    <description>FEV1 predose assessment as lung function parameter</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Clenil® Modulite® via AeroChamber Plus™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clenil® Modulite® administered via AeroChamber Plus™ spacer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clenil® Modulite® via Volumatic™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clenil® Modulite® administered via Volumatic™ spacer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clenil® Modulite® via AeroChamber Plus™ plus charcoal block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clenil® Modulite® administered via AeroChamber Plus™ spacer plus charcoal block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clenil® Modulite® via Volumatic™ plus charcoal block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clenil® Modulite® administered via Volumatic™ spacer plus charcoal block</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clenil® Modulite® via AeroChamber Plus™</intervention_name>
    <description>Clenil® Modulite® 250 µg via AeroChamber Plus™ spacer during 14 days</description>
    <arm_group_label>Clenil® Modulite® via AeroChamber Plus™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clenil® Modulite® via Volumatic™ spacer</intervention_name>
    <description>Clenil® Modulite® 250 µg via Volumatic™ spacer during 14 days</description>
    <arm_group_label>Clenil® Modulite® via Volumatic™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clenil® Modulite® via AeroChamber Plus™ plus charcoal block</intervention_name>
    <description>Clenil® Modulite® via AeroChamber Plus™ spacer during 14 days (plus charcoal block at Day 14)</description>
    <arm_group_label>Clenil® Modulite® via AeroChamber Plus™ plus charcoal block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clenil® Modulite® administered via Volumatic™ spacer plus charcoal block</intervention_name>
    <description>Clenil® Modulite® administered via Volumatic™ spacer during 14 days (plus charcoal block at day 14)</description>
    <arm_group_label>Clenil® Modulite® via Volumatic™ plus charcoal block</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non-pregnant female patients aged 18-65 years included.

          -  Diagnosis of asthma according to GINA guidelines 2009 made at least 6 months prior to
             screening.

          -  Patients already treated with a dose of BDP or equivalent up to 2000 µg/day.

          -  FEV1 ≥ 60% of predicted for the patient's normal value at screening and randomisation

        Exclusion Criteria:

          -  Patients treated with oral or parenteral corticosteroids in the previous 8 weeks (12
             weeks for parenteral depot corticosteroids) before screening visit.

          -  Exacerbation of asthma symptoms or hospitalization due to asthma exacerbation within
             the previous one month before screening until randomisation.

          -  Lower respiratory tract infection within one month prior to screening.

          -  Diagnosis of COPD as defined by the current GOLD 2009 (Global Initiative for Chronic
             Obstructive Lung Disease) Guidelines.

          -  Significant medical history and/or treatments for cardiac, renal, neurological,
             hepatic, endocrine diseases, or any laboratory abnormality indicative of a significant
             underlying condition, that may interfere with patient's safety, compliance, or study
             evaluations, according to the Investigator's opinion.

          -  Treatment with a xanthine derivative (e.g. theophylline) formulation in the 4 weeks
             prior to screening.

          -  Any enzyme inducing or inhibiting drug (from 8 weeks before screening visit)

          -  Patients who received any investigational new drug within the last 8 weeks before the
             screening. The patients cannot participate in another clinical study at the same time
             as the present study.

          -  Blood donation (450 mL or more)or significant blood loss less than 12 weeks before the
             first intake of study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dave Singh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medicine Evaluation Unit, Manchester, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medicines Evaluation Unit, Wythenshawe Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022615-19</url>
    <description>Study Record on EU Clinical Trials Register including results</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2011</study_first_submitted>
  <study_first_submitted_qc>June 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2011</study_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>PK</keyword>
  <keyword>Adults</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Beclomethasone</mesh_term>
    <mesh_term>Charcoal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

